Revance Therapeutics Inc (NASDAQ:RVNC)
| 21.22 Delayed Data As of May 22 |  +0.34 / +1.63%Today’s Change | 9.88 Today|||52-Week Range 27.97 | +30.75% Year-to-Date |
Latest RVNC News | Press Releases
No recent news for Revance Therapeutics Inc.
Today’s Trading
| Previous close | 20.88 |
| Today’s open | 20.88 |
| Day’s range | 20.54 - 21.26 |
| Volume | 50,435 |
| Average volume (3 months) | 837,803 |
| Market cap | $1.2B |
Data as of 3:59pm ET, 05/22/2020
Growth & Valuation
| Earnings growth (last year) | +6.93% |
| Earnings growth (this year) | -30.21% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -88.92% |
| P/E ratio | NM |
| Price/Sales | 1,707.91 |
| Price/Book | 4.94 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ESPREsperion Therapeutic... | -0.49 | -1.12% |
| ARCTArcturus Therapeutic... | +4.28 | +7.91% |
| MGNXMacroGenics Inc | +0.21 | +0.83% |
| ZEALZealand Pharma A/S | -0.10 | -0.29% |
Data as of 4:57pm ET, 05/22/2020
Financials
| Next reporting date | July 30, 2020 |
| EPS forecast (this quarter) | -$0.99 |
| Annual revenue (last year) | $413.0K |
| Annual profit (last year) | -$159.4M |
| Net profit margin | -38,602.66% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
No executives to display |
Corporate headquarters Newark, California |
Forecasts
